全文获取类型
收费全文 | 11002篇 |
免费 | 526篇 |
国内免费 | 56篇 |
专业分类
耳鼻咽喉 | 115篇 |
儿科学 | 201篇 |
妇产科学 | 246篇 |
基础医学 | 1239篇 |
口腔科学 | 344篇 |
临床医学 | 865篇 |
内科学 | 3020篇 |
皮肤病学 | 150篇 |
神经病学 | 1133篇 |
特种医学 | 345篇 |
外科学 | 1406篇 |
综合类 | 26篇 |
一般理论 | 3篇 |
预防医学 | 490篇 |
眼科学 | 207篇 |
药学 | 762篇 |
中国医学 | 14篇 |
肿瘤学 | 1018篇 |
出版年
2024年 | 12篇 |
2023年 | 67篇 |
2022年 | 150篇 |
2021年 | 280篇 |
2020年 | 170篇 |
2019年 | 228篇 |
2018年 | 254篇 |
2017年 | 220篇 |
2016年 | 252篇 |
2015年 | 272篇 |
2014年 | 363篇 |
2013年 | 543篇 |
2012年 | 791篇 |
2011年 | 810篇 |
2010年 | 452篇 |
2009年 | 429篇 |
2008年 | 757篇 |
2007年 | 812篇 |
2006年 | 774篇 |
2005年 | 736篇 |
2004年 | 742篇 |
2003年 | 642篇 |
2002年 | 582篇 |
2001年 | 99篇 |
2000年 | 78篇 |
1999年 | 71篇 |
1998年 | 115篇 |
1997年 | 78篇 |
1996年 | 82篇 |
1995年 | 78篇 |
1994年 | 79篇 |
1993年 | 69篇 |
1992年 | 62篇 |
1991年 | 38篇 |
1990年 | 46篇 |
1989年 | 37篇 |
1988年 | 27篇 |
1987年 | 36篇 |
1986年 | 31篇 |
1985年 | 28篇 |
1984年 | 27篇 |
1983年 | 27篇 |
1982年 | 20篇 |
1981年 | 28篇 |
1980年 | 13篇 |
1979年 | 9篇 |
1978年 | 9篇 |
1977年 | 9篇 |
1967年 | 7篇 |
1966年 | 5篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
101.
Fazio G Mongiovi' M Sutera L Novo G Novo S Pipitone S 《International journal of cardiology》2008,123(2):e31-e34
Wolff-Parkinson-White (WPW) is a syndrome characterized by the presence of an accessory pathway that skipping A-V node may lead the electrical stimulus from the atrium directly to the ventricle. Some studies reported the finding of myocardial dyskinesia in the segments precociously activated by the accessory pathway, at echocardiogram and at nuclear cardiac study. Soria et al. reported, in 1985, an increased incidence of dilative cardiomyopathy in patients with WPW. The pathophysiological pathway that leads to ventricular dilation may be due to the increase of end-diastolic pressure secondary to a tachycardia-induced cardiomyopathy. Tachycardia-induced cardiomyopathy is usually secondary to frequent and prolonged tachycardia episodes. In this paper we report the cases of three patients affected by WPW who developed dilative cardiomyopathy during the follow-up. Particularly dyskinetic segments, working such as a functional aneurysm, could induce deep modifications of intraventricular haemodynamics, leading to remodelling and progressive ventricular dilation. This hypothesis could have important empirical consequences because it could imply the necessity of a precocious ablative therapy in this kind of patients. 相似文献
102.
103.
Spironolactone improves lung diffusion in chronic heart failure. 总被引:1,自引:0,他引:1
Piergiuseppe Agostoni Alessandra Magini Daniele Andreini Mauro Contini Anna Apostolo Maurizio Bussotti Gaia Cattadori Pietro Palermo 《European heart journal》2005,26(2):159-164
AIMS: To evaluate whether anti-aldosteronic treatment influences lung diffusion (DLCO) in chronic heart failure (HF) patients. Spironolactone improves clinical conditions and prognosis in chronic HF and reduces connective tissue matrix turnover; DLCO abnormalities in chronic HF are related to increase in fibrosis and connective tissue derangement. METHODS AND RESULTS: Thirty stable chronic HF patients, with reduced DLCO (<80% of predicted), were randomly assigned to active treatment (25 mg spironolactone daily) or placebo in addition to conventional anti-failure treatment. They were evaluated by quality of life questionnaire, laboratory investigations, cardiopulmonary exercise test, and pulmonary function test, which included DLCO and membrane diffusing capacity (DM). The evaluation was done before treatment and 6 months after. Quality of life score and standard pulmonary function tests were not significantly affected by spironolactone, while active treatment increased DLCO due to an increase of DM (DLCO: 18.3+/-3.9 vs. 19.9+/-5.5 mL/min/mmHg; DM: 28.1+/-7.7 vs. 33.3+/-8.6 mL/min/mmHg) and peak oxygen consumption (peak VO2 16.8+/-1.9 vs.18.6+/-2.2 mL/min/kg). Increments of DLCO and peak VO2 were linearly related (R=0.849, P<0.001). CONCLUSION: These data show a positive effect of spironolactone on gas diffusion and exercise capacity suggesting a novel mechanism by which anti-aldosteronic drugs improve HF clinical condition and prognosis. 相似文献
104.
Vignini A Nanetti L Moroni C Testa R Sirolla C Marra M Manfrini S Fumelli D Marcheselli F Mazzanti L Rabini RA 《Nutrition, metabolism, and cardiovascular diseases : NMCD》2008,18(1):15-22
Background and aimType 2 diabetic (T2DM) patients show decreased fibrinolysis, mainly linked to high plasminogen activator inhibitor type 1 (PAI-1) production, together with a reduced bioavailability of nitric oxide and an impairment in Na+/K+-ATPase activity possibly involved in increased cardiovascular risk. Vitamin E is the major natural lipid-soluble antioxidant in human plasma. The present work was conducted in order to measure PAI-1, ICAM and VCAM-1 plasma levels, platelet nitric oxide production and membrane Na+/K+-ATPase activity in type 2 diabetic subjects treated with vitamin E (500 IU/day) for 10 weeks and then followed for other 20 weeks.Methods and resultsThirty-seven T2DM patients (24 males and 13 females) were studied. None of them were affected by any other disease or diabetic complications. Significant differences were detected for PAI-1 antigen (p < 0.001), PAI-1 activity (p < 0.001), nitric oxide (NO) production (p < 0.001), and Na+/K+-ATPase activity (p < 0.001) among the 4 phases of the study. A significant decrease both in ICAM and VCAM-1 plasma levels was also found at the 10th week compared with baseline (respectively p < 0.001 and p < 0.05).ConclusionOur data suggest that vitamin E counteracts endothelial activation in T2DM patients possibly representing a new tool for endothelial protection. 相似文献
105.
Hypertension and hypercholesterolemia are frequently associated, and their treatment is proven to reduce cardiovascular risk.
Current guidelines on cardiovascular prevention strongly recommend treating both disorders. Unfortunately, the low treatment
and control rates, combined with the high prevalence of both conditions, still contribute to the high burden of cardiovascular
disease in Western countries. In the past 5 years, many studies evaluating the benefit of combined antihypertensive and lipid-lowering
treatment on endothelial dysfunction, coronary atherosclerosis, hypertension control, and on primary and secondary prevention
of cardiovascular events have been published. In this article, we discuss and critically evaluate the available evidence on
the potential benefits of combined antihypertensive and lipid-lowering treatment. 相似文献
106.
Elena Geuna Andrea Milani Rossella Martinello Caterina Aversa Giorgio Valabrega Maurizio Scaltriti 《Expert opinion on investigational drugs》2015,24(3):421-431
Introduction: Deregulation of the phosphatidylinositol-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) intracellular signaling pathway is common in breast cancer (BC) and has been found to be potentially implicated in resistance to endocrine and anti-HER2 therapies. Targeting the PI3K/Akt/mTOR pathway may remove this inhibition and restore sensitivity to these compounds. Buparlisib (BKM120) is a potent oral pan-class I PI3K inhibitor that is being extensively evaluated in multiple tumor types.Areas covered: This review briefly summarizes the pharmacodynamics and pharmacokinetics of buparlisib, focusing on preclinical and clinical data in BC and on ongoing randomized trials.Expert opinion: Overall, buparlisib is a safe and tolerable drug and, despite its peculiar toxicity profile, it is suitable for studies in combination with other anticancer agents in BC. Early-phase clinical trials in BC have provided evidence of antitumor activity. Several trials are being conducted in all the biological subsets of BC, including combinations with endocrine therapy, anti-HER2 agents, PARP-inhibitors and chemotherapy. While clinical results are eagerly awaited, biological material suitable for both genomic and non-genomic analyses is being collected. The authors expect an intense investigation of the potential biomarkers that explain response or resistance to buparlisib and inspire strategies to rationally explore the therapeutic potential of this drug. 相似文献
107.
Bixio Riccardo Bertelle Davide Pistillo Francesca Pedrollo Elisa Carletto Antonio Rossini Maurizio Viapiana Ombretta 《Clinical rheumatology》2022,41(4):1247-1254
Clinical Rheumatology - Myasthenia gravis is an autoimmune disease affecting the neuromuscular junction, often associated with other autoimmune diseases, including rheumatoid arthritis. Patients... 相似文献
108.
De Feo M Onorati F Renzulli A Gregorio R Vicchio M Vitale N Cotrufo M 《The Journal of heart valve disease》2004,13(1):103-108
BACKGROUND AND AIM OF THE STUDY: Thromboembolism and hemorrhage related to anticoagulation remain a major concern in elderly patients with mechanical valves. Clinical results following isolated aortic valve replacement (AVR) with tilting disk and bileaflet prostheses in patients aged over 70 years were analyzed and compared with results in patients aged <45 years. METHODS: Between January 1980 and August 2002, 319 consecutive older patients (group A) and 497 young patients AVR. Preoperative clinical data, early and late mortality, valve-related complications and data related to anticoagulation status (including mean INR and mean interval between INR assays) were compared between groups. RESULTS: Hospital mortality was lower in group B (3.4%) than in group A (10.7%; p <0.0001). Twelve-year actuarial survival was lower in older patients (54% in group A versus 78% in group B; p <0.001). The two groups showed similar 12-year actuarial freedom from hemorrhage (99.6% versus 99.5%; p = 0.69), endocarditis (99.6% versus 98.43%; p = 0.25) and perivalvular leak (99.6% versus 97.9%; p = 0.21). However, actuarial freedom from thromboembolism was lower in older patients (98.8% versus 99.7%; p = 0.041). CONCLUSION: Despite lower rates of long-term mortality and thromboembolism (the latter because of advanced atherosclerosis) in group A, there were no differences in rates of other valve-related complications. Hence, older age cannot be considered a contraindication to implantation of mechanical valves in the aortic position. 相似文献
109.
Risk of cardiovascular disease in relation to achieved office and ambulatory blood pressure control in treated hypertensive subjects 总被引:2,自引:0,他引:2
Verdecchia P Reboldi G Porcellati C Schillaci G Pede S Bentivoglio M Angeli F Norgiolini S Ambrosio G 《Journal of the American College of Cardiology》2002,39(5):878-885
OBJECTIVE: We investigated the prognostic impact of 24-h blood pressure control in treated hypertensive subjects. BACKGROUND: There is growing evidence that ambulatory blood pressure improves risk stratification in untreated subjects with essential hypertension. Surprisingly, little is known on the prognostic value of this procedure in treated subjects. METHODS: Diagnostic procedures including 24-h noninvasive ambulatory blood pressure monitoring were undertaken in 790 subjects with essential hypertension (mean age 48 years) before therapy and after an average follow-up of 3.7 years (2,891 patient-years). RESULTS: At the follow-up visit, 26.6% of subjects achieved adequate office blood pressure control (<140/90 mm Hg), and 37.3% of subjects achieved adequate ambulatory blood pressure control (daytime blood pressure <135/85 mm Hg). Months or years after the follow-up visit, 58 patients suffered a first cardiovascular event. Event rate was lower (0.71 events/100 person-years) among the subjects with adequate ambulatory blood pressure control than among those with higher blood pressure levels (1.87 events/100 person-years) (p = 0.0026). Ambulatory blood pressure control predicted a lesser risk for subsequent cardiovascular disease independently of other individual risk factors (RR 0.36; 95% confidence intervals: 0.18 to 0.70; p = 0.003), including age, diabetes and left ventricular hypertrophy. Office blood pressure control was associated with a nonsignificant lesser risk of subsequent events (RR 0.63; 95% confidence intervals: 0.31 to 1.31; p = NS). In-treatment ambulatory blood pressure was more potent than pre-treatment blood pressure for prediction of subsequent cardiovascular disease. CONCLUSIONS: Ambulatory blood pressure control is superior to office blood pressure control for prediction of individual cardiovascular risk in treated hypertensive subjects. 相似文献
110.
BACKGROUND/AIMS: The identification of metabolic and environmental predictors of excess body fat is still far from being achieved. The aim of this study was to evaluate whether respiratory quotient in non-obese women is a predictor of body weight changes after a 6-year follow-up period. METHODS: Forty-three non-obese healthy women participated in the study. Their baseline general characteristics were: age 40.5 +/- 12.8 years; height 159 +/- 7 cm; weight 61.8 +/- 10.1 kg, and body mass index (BMI) 24.4 +/- 3.8 kg/m2. At baseline basal metabolic rate and respiratory quotient were determined by indirect calorimetry, while weight and BMI were recorded at the first observation and after the 3- and 6-year follow-ups. RESULTS: At the first observation basal metabolic rate was 5,360 +/- 713 kJ/day and respiratory quotient 0.850 +/- 0.052. After 6 years, with weight changes equal to 1.4 +/- 4.5 kg, baseline respiratory quotient was a significant predictor (p < 0.05) of changes in body weight or BMI together with baseline BMI. CONCLUSIONS: This follow-up study confirms that a high respiratory quotient (measured on free diet) predisposes to weight gain, especially in women with the highest baseline respiratory quotient (above the 90th percentile of the distribution for this variable). 相似文献